Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian sarcoma group phase II study

This publication has 29 references indexed in Scilit:

• Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials
  British Journal of Cancer, 1995
• Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
  Journal of Clinical Oncology, 1995
• Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide
  Cancer Chemotherapy and Pharmacology, 1995
• Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
  Journal of Clinical Oncology, 1994
• Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
  Journal of Clinical Oncology, 1993
• Does histologic grade in soft tissue sarcoma influence response rate to systemic chemotherapy?
  Cancer, 1991
• Chemotherapy for metastatic soft tissue sarcomas – another full circle?
  British Journal of Cancer, 1991
• The pharmacology of intravenous and oral etoposide
  Cancer, 1991
• Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
  Journal of Clinical Oncology, 1989
• Phase II Study of Ifosfamide-Etoposide-Mesna in Adults With Advanced Nonosseous Sarcomas
  JNCI Journal of the National Cancer Institute, 1989